<DOC>
	<DOCNO>NCT00252382</DOCNO>
	<brief_summary>The purpose study evaluate objective tumor response rate ( base RECIST criterion ) SNS-595 second-line therapy patient advance NSCLC .</brief_summary>
	<brief_title>Safety Efficacy Clinical Study SNS-595 Second-Line Therapy Patients With Advanced NSCLC</brief_title>
	<detailed_description>Other objective study assess safety , tumor response , time disease progression , survival rate explore several potential biomarkers see level change administration SNS-595 .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Able understand willing sign write informed consent document Patients recurrent metastatic NSCLC , fail initial therapy platinumcontaining regimen receive secondline therapy ( adjuvant therapy acceptable complete great equal 12 month cancer recurrence ) Measurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Laboratory Values within normal reasonable reference range specify protocol Prior exposure SNS595 Pregnant breastfeed Women childbearing potential male partner woman childbearing potential unwilling use approve , effective mean contraception accord institution 's standard Other active malignancy malignancy within past 12 month except nonmelanoma skin cancer , cervical intraepithelial neoplasia prostatic intraepithelial neoplasia Brain metastasis , present , without radiologic evidence progressive disease least 3 month completion therapy Myocardial infarction , cerebrovascular accident/transient ischemic attack ( TIA ) thromboembolic event ( deep vein thrombosis pulmonary embolus ) within 6 month first SNS595 dose Requires kidney dialysis ( hemodialysis peritoneal ) Prior chemotherapy , investigational agent , radiation therapy within 28 day Cycle 1 Day 0 ; however , nitrosoureas mitomycin permit least 42 day Cycle 1 Day 0 In patient toxicity cause prior cancer therapy , toxicity must return less equal Grade 1 , exception alopecia Prior pelvic radiation therapy radiation great equal 25 % bone marrow reserve ( prior palliative radiation permit long exceed 25 % bone marrow reserve ) Any medical , psychological , social condition , opinion Principal Investigator , would contraindicate patient 's participation clinical trial due safety concern compliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Lung</keyword>
	<keyword>Squamous Cell</keyword>
	<keyword>Large Cell</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Cancer</keyword>
</DOC>